VCELVericel Corporation

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+35.6% YoY

Gross Profit

$21M69.4% margin

Operating Income

$3M10.2% margin

Net Income

$3M11.4% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

+16.6%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$7M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$138M

Total Liabilities

$41M

Stockholders' Equity

$97M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$22M	+35.6%
Gross Profit	$21M	$14M	+47.6%
Operating Income	$3M	-$1M	+331.8%
Net Income	$3M	-$1M	+424.6%

Revenue Segments

Product

$30M100%

VCEL Q3 2019 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena